Bhavna Saraiya, MD
Internal Medicine · Petersburg, VANPI 1215102819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Lilly USA, LLC at 27.7% of the total.
Across 37 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$200
- Abbott$105
- Exact Sciences$74
- Lifescan, Inc.$57
- AbbVie$35
- Boehringer Ingelheim$35
- plus $215 from 8 others
Across 1 payment — averaging $464.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$464
What the payments were for
- Food & beverage$68795%
- Education$355%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $200 |
| Abbott | 5 | $105 |
| Exact Sciences | 4 | $74 |
| Lifescan, Inc. | 2 | $57 |
| AbbVie | 2 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Novo Nordisk | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $28 |
| AstraZeneca | 2 | $27 |
| Dynavax Technologies Corporation | 1 | $26 |
| Aroa Biosurgery Incorporated | 1 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
How this compares
$722 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 152 | $129,324 |
| OzempicSemaglutide | 53 | $80,267 |
| TrulicityDulaglutide | 25 | $40,678 |
| EliquisApixaban | 28 | $28,547 |
| JanuviaSitagliptin Phosphate | 22 | $17,051 |
| LinzessLinaclotide | 18 | $15,592 |
| FarxigaDapagliflozin Propanediol | 20 | $15,113 |
| Victoza 3-PakLiraglutide | 12 | $14,059 |
| XareltoRivaroxaban | 15 | $12,160 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $10,539 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 179 | $5,551 |
| Metoprolol Succinate | 377 | $4,437 |
| Losartan Potassium | 468 | $4,383 |
| Amlodipine Besylate | 854 | $4,023 |
| Atorvastatin Calcium | 492 | $3,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $35 | $129,324152 claims |
| Novo NordiskOzempic | $30 | $80,26753 claims |
| Lilly USA, LLCTrulicity | $200 | $40,67825 claims |
| AstraZenecaFarxiga, Symbicort | $27 | $25,65250 claims |
| AbbVieLinzess | $35 | $15,59218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Petersburg
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Denise BrunerArlington$227K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.